博动医学 (founded September 2015 in Shanghai) develops multimodal vascular interventional imaging and physiology products across the care pathway from screening to intraoperative diagnosis and post‑op assessment. Its core technologies include angiography‑based QFR (non‑wire, rapid FFR computation), CT‑QFR, IVUS/OCT systems and a line of integrated interventional consumables (including an IVUS/OCT/QFR tri‑mode catheter). The company holds 70+ patents across China, the U.S., Germany and Japan, and four products are in China NMPA innovation/priority review with CE certification for several devices and two NMPA registrations. Extensive clinical evidence (20+ countries, >100 studies, >20,000 cases) shows QFR improves diagnostic accuracy by ~33% and has strong academic acceptance; a large RCT (FAVOR III China) was expected to report results in November 2021. Commercial traction includes average adoption where QFR is routinely offered (2020–2021 hospitals report >30% of angiography patients choosing QFR) and strategic partnerships with Philips and leading Chinese hospitals and universities. The company plans to use new funding to accelerate commercialization, new‑product R&D, clinical registrations and global expansion into additional vascular intervention areas (brain, peripheral) to broaden its clinical and market footprint.

Total raised

$100M

Funding rounds

1

Latest round

Series C

Latest activity

Aug 2021